MedTrace Logo

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCT05672121 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-11-27

No results posted yet for this study

Summary

KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

KH631

KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Sponsors & Collaborators

  • Chengdu Origen Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wenbin Wei, PhD · Beijing Tongren Hospital Affiliated to Capital Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-06
Primary Completion
2026-12-28
Completion
2026-12-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672121 on ClinicalTrials.gov